IOL Chemicals and Pharmaceuticals Ltd has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines (EDQM) for its Metformin Hydrochloride Process-II. This approval strengthens the company’s global pharmaceutical footprint, enabling wider market access and reinforcing its commitment to quality and compliance.
IOL Chemicals and Pharmaceuticals Ltd announced that the EDQM has granted a CEP for its Metformin Hydrochloride Process-II. This certification is a significant milestone, enhancing the company’s ability to supply active pharmaceutical ingredients (APIs) to regulated markets worldwide.
Regulatory Achievement
The CEP approval validates IOL Chemicals’ adherence to stringent European quality standards. It allows the company to expand its presence in international markets, particularly in Europe, where regulatory compliance is critical for pharmaceutical exports.
Key Highlights
-
EDQM grants CEP for Metformin Hydrochloride Process-II
-
Certification strengthens IOL Chemicals’ global pharmaceutical footprint
-
Enables wider access to regulated European markets
-
Reinforces commitment to quality, compliance, and innovation
Outlook
With this approval, IOL Chemicals is positioned to enhance its export potential and strengthen partnerships with global pharmaceutical companies. The certification underscores the company’s focus on regulatory excellence and long-term growth in the healthcare sector.
Sources: Company announcement via stock exchange filings